Ractigen Therapeutics completes trial enrolment for ALS drug
Ractigen Therapeutics completed patient enrolment and initial dosing across all cohort groups in its Phase II clinical trial evaluating RAG 17 for ALS treatment
NANTONG, China - Ractigen Therapeutics, a clinical-stage biotech firm focusing on RNA therapies, has announced the completion of patient enrollment and initial dosing in its Phase II ALS drug trial for RAG-17. This milestone follows the successful dosing of the first participant on January 13, 2026, and marks the end of patient enrollment across all five trial sites.
RAG-17, an investigational siRNA therapy targeting SOD1 mutations in amyotrophic lateral sclerosis (ALS), is developed using Ractigen's SCAD™ platform. The Phase II trial, NCT06556394, aims to assess the drug's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in SOD1-mutation patients. With regulatory interactions and potential approval on the horizon, Ractigen remains focused on advancing RAG-17 through the accelerated development pathway designated by the FDA and selected for the CARE Program by the National Medical Products Administration.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
